GenSight up after gene therapy gets PIM designation in UK

Gensight Biologics SA

06/09/2021 09:56

** Shares in GenSight Biologics  SIGHT.PA  rise 1.5% as the
UK's Medicines and Healthcare products Regulatory Agency (MHRA)
granted its gene therapy LUMEVOQ "promising innovative medicine"
(PIM) designation  urn:newsml:reuters.com:*:nFWN2Q50RQ
    ** The PIM designation is the first step of the MHRA's early
access to medicines scheme (EAMS) in the treatment, diagnosis or
prevention of life-threatening or seriously debilitating
conditions with an unmet need
    ** The scheme covers medicines that are not yet available as
licensed treatments and is a pre-requisite to enter the EAMS
scientific opinion assessment
    ** The stock, which jumped as much as 4.9% in early trading,
is up more than 15% year-to-date

 (Reporting by Juliette Portala)
 ((juliette.portala@tr.com))